Neuraxpharm

⏲️ The countdown is on for #IEC2025! The #Neuraxpharm team is looking forward to joining experts in epilepsy research at the 36th International Epilepsy Congress, taking place in Lisbon from 30 August – 3 September. Organised by the International League Against Epilepsy, this global meeting brings together leading healthcare professionals and scientists dedicated to advancing epilepsy care for an event packed with expert sessions, symposiums, and workshops to inspire innovation, collaboration and change. Make sure to visit us at Booth #214 to meet our team, exchange insights, and explore how Neuraxpharm continues to support the epilepsy community. We can’t wait to connect with you in Lisbon! #ILAE #Epilepsy #HealthcareCommunity #HealthcareInnovation #CNS #Neurology

Today we've launched our Sustainability Report for 2024! Here we outline the key milestones and progress made in our sustainability journey, reflecting our continued commitment to responsibility, transparency and long-term value creation.    🌍 As a leading European #CNS specialist expanding our footprint globally, we remain committed to improving the lives of the CNS community while upholding the highest standards of environmental, social and corporate responsibility during this defining year for Neuraxpharm.   Follow our sustainability journey in this year's report, which showcases a broader and more integrated view of our environmental, social and governance efforts.   We look forward with optimism and determination to the year ahead, driven by our mission to improve patient outcomes while always adhering to the highest ethical standards.   🔗 Click here to read the full report: https://lnkd.in/e2PSzEk5   #Sustainability #SustainabilityReport #Pharma #CNS #PatientCare 

#Neuraxpharm welcomes you back to another episode in our Unfiltered Executive series where we go behind the scenes to shine a spotlight on our Executive Committee.   Joining us in the latest edition is our Chief Business Development and Innovation Officer, Miguel Barrero Durán!   Following 25 years of experience in the pharmaceutical industry, Miguel gives a fascinating insight into what motivates him and what he hopes his legacy will be at Neuraxpharm, plus his thoughts on the best part of being a leader of our business development and innovation team.   On a personal level, we discover Miguel’s dreams and goals. Did you know he’s an endurance athlete who has twice competed in the Ironman World Championship in Hawaii and completed the Marathon des Sables across the Sahara Desert—twice? 🏃♂️ 👇 Watch the video to learn more!   #CNS #CNSDisorders #Pharma #Healthcare

📢 News update: #Neuraxpharm and Minoryx Therapeutics announced today that the Marketing Authorization Application (MAA) for Minoryx’s lead candidate #leriglitazone (NEZGLYAL®) has been submitted to the European Medicines Agency (EMA) for the treatment of paediatric and adult male patients with cerebral adrenoleukodystrophy (#cALD).   This new MAA is based on recent data from the successfully concluded NEXUS study, a 96-week, pivotal, open-label study designed to evaluate the efficacy and safety of once-daily oral dosing of leriglitazone in paediatric patients with cALD.   Read the press release to find out more about the NEXUS study, in which the primary endpoint was met. Click the link 👉 https://lnkd.in/dHNYFxag   EMA has now validated the MAA file and it is under review by the Committee for Medicinal Products for Human Use (CHMP).   #CNS #cALD #pharmaceuticals #pharma

📢 News alert #Neuraxpharm launches new affiliate - Neuraxpharm Australia.   Following the opening of Neuraxpharm Middle East in 2024 and the establishment of affiliates in Brazil and Mexico in 2023, we are expanding Neuraxpharm's operations to Australia, with our affiliate based in Sydney.   As Europe's CNS specialist, we remain committed to bringing innovative CNS treatments to patients across Europe and beyond. This expansion will enable greater and improved patient access to treatments.   🌏 Leading Neuraxpharm Australia will be Avendran Naidu, newly appointed as Head of Commercial. Bolstered by Avendran's over 15 years of commercial sales and leadership experience in the pharmaceutical industry, Neuraxpharm Australia will commercialise and offer important additions to the #CNS treatments currently available to Australian patients. As part of Neuraxpharm's growth strategy in this significant CNS market, additional leading CNS treatments from Neuraxpharm's portfolio are expected to follow.   Discover more about Neuraxpharm's mission to commercialise innovative solutions for CNS disorders to improve patient outcomes and well-being. 🔗 Read more in the press release here: https://lnkd.in/djEfBAAd   #CNS #Pharma #Healthcare #CNSDisorders #NeuraxpharmAustralia

☀️ Seizures don’t take a summer holiday—but with a bit of planning, you can reduce the risk and enjoy the season safely.   During summer, some common seizure triggers are more likely to occur: 🔹 Lack of sleep – Late nights and long travel days can disrupt routine 🔹 Dehydration – Heat and outdoor activities increase fluid loss 🔹 Skipped meals – Busy days can lead to missed meals and unstable blood sugar   Here’s how to stay prepared: ✅ Stick to consistent sleep schedules, even while travelling ✅ Drink plenty of water throughout the day ✅ Pack healthy snacks to maintain regular meals   Taking simple steps can make a big difference in keeping seizures at bay and making the most of your summer. Neuraxpharm’s ACT FAST, STOP SEIZURES, SAVE LIVES campaign highlights the urgency of recognizing and responding to prolonged convulsive seizures. Find out more here: https://lnkd.in/dFpeFBFu  #ActFastStopSeizuresSaveLives #EpilepsyAwareness #SummerSafety #SeizureFirstAid #Pharma

A powerful moment for epilepsy care at EPNS 2025! 🙌 We were honoured to contribute to the scientific programme of the European Paediatric Neurology Society (EPNS) Congress with our symposium on improving emergency seizure management in community settings. Our faculty of experts shared critical insights on: 🧠 The clinical consequences of delayed seizure intervention 📝 The role of clear seizure action plans 📌 The latest recommendations for managing seizure emergencies outside the hospital A huge thank you to our speakers and everyone who attended and engaged in this vital conversation. At Neuraxpharm, we’re committed to supporting healthcare professionals and collaborating with the scientific community to improve outcomes for children living with epilepsy. #EPNS2025 #EpilepsyAwareness #CNS #Neuraxpharm #PaediatricNeurology #ActFastStopSeizuresSaveLives #SeizureCare #PatientSafety #Pharma

📰 #Neuraxpharm features in pharmaphorum’s round-up of Biotechnology Innovation Organization (BIO) International Convention 2025 📰   The article outlines significant trends and themes from the largest and most comprehensive event for biotechnology, held in Boston this June. In attendance was our Chief Business Development and Innovation Officer, Miguel Barrero Durán, who discusses the integration of AI into drug development. Miguel highlights that biotech is entering “a transformative era”, although “a key challenge persists: ensuring equitable access to these breakthroughs.”   Joining Barrero was colleague Charles Morris, Chief Corporate Development Officer. Charles expresses that “the biggest challenge the industry continues to face is where new drugs will come from to address unmet medical needs.”   As Europe’s #CNS specialist, we are committed to delivering innovative solutions which improve the well-being and quality of life for patients with psychiatric and neurological conditions.   📖 Click the link for more insights, key takeaways and the issues facing biotech today 👉 https://lnkd.in/ejAiTtBR   #BIO2025 #Biotech #InnovationInCNS #CNS

Join us at EPNS 2025 in Munich! We’re proud to sponsor the European Paediatric Neurology Society (EPNS) Congress, taking place from 8–12 July at the ICM in Munich. 📍 Visit us at Booth #112 📅 Attend our sponsored symposium: “ACT FAST: Refining our approach to managing prolonged seizures in the community” 🗓️ 11 July | 13:00–14:00 CET 📍 Room 13b, ICM Munich Our expert speakers will share the latest recommendations and real-world insights on rapid seizure intervention outside of the hospital setting – including seizure action plans and the importance of early rescue medication. Let’s connect and discuss how we can advance care for children living with epilepsy. See you in Munich! #EPNS2025 #EpilepsyCare #ChildNeurology #CNS #Neuraxpharm #PaediatricNeurology #ActFastStopSeizuresSaveLives #Pharma #SeizureFirstAid

🤝 Neuraxpharm has entered into a global strategic co-development agreement with Dizlin Pharmaceuticals AB for Infudopa SubC® – a next-generation drug-device therapy for advanced #Parkinson’s disease.   This is a pivotal milestone for Neuraxpharm as we take our first step into the drug-device space with a combination therapy that reinforces our commitment to innovation in CNS. By combining pharmaceutical and device expertise, we aim to deliver a more accessible, minimally invasive treatment that enables flexible dosing and encourages greater independence for people living with Parkinson’s.   Neuraxpharm is proud to be the partner of choice in #CNS disorders. 👉 Discover how we’re shaping the future of advanced Parkinson’s treatment. Read the full press release here: https://lnkd.in/dMPEMn_9   #ParkinsonsDisease #DrugDevice #MedTech #CNSDisorders #Pharma #Neurology #PatientCare